UMKC/UWC Data Analytics Training in Health Sciences Fellowship

64108

Unit: Division of Pharmacology and Pharmaceutical Sciences

Contact: (816) 235 962; wyckoffg@umkc.edu

Abstract from proposal:

Our partnership seeks to increase the capacity for data science research and innovation in the health and life sciences in Africa by supporting trainees from the University of the Western Cape (UWC) in a robust training environment within the University of Missouliciansas City (UMKC). As a capacity building proposal, the goal is to offer opportunities to UWC scholars to enable them to become the next generation of research leaders for collaborative work. By establishing a visiting scholar program between UWC and UMKC centering around our shared schools of Pharmacy, we will address deficiencies in a submitted Disa training proposal which will allow us to be successful with a subsequent submission. There have three rous examples of successful collaborations across the nearly 20 history of this partnership at UMKC, some highly relevant examples include the UMKC Mathematics and Statistics department hosting UWC investigators, as well as teaching a numerially is course at UWC; Dentistry hosting several visiting scholars; and current joint grant development efforts between UMKC and UWC Pharmacy schools as well as engagement between the Bloch School. We seek to build a more formal exchange of scholars of schort-term, regular basis to address challenging problems in health data analytics.

Overall, the goal was to have four UWC scholars visit UMKC, and Dr. Wyckoff visit UWC, in order to develop new opportunities for fundable research.

Proposed outcomes:

- 1) Each student will be expected to submit at least one paper on work that was produced, in whole or in part, during the collaborative period funded by this work.
- 2) Each student will be expected to graduate within 12 to 14 months from participation in this program.
- 3) At the conclusion of the program, a seminar will be held at UWC to highlight the work performed by the students during the collaboration.
- 4) At least one faculty member who can champion a U2R submission focused on data analysis in health serices at UWC will be identified at the end of this project. 5) Creation of the ^s]•]*]vP ^ Z}o OE•_ % OE}POE u

Adjustments:

Due to some ongoing Visa delays, as well as match of scholars and projects, three out of four of the scholars supported were more seniand had already achieved their PhD. Therefore, the metric of graduation within 18 months was not applicable. However, these scholars were asked to develop new projects that could be fundable from their work at UMKC.

TravelActivities:

data analysis. Dr. Breytenbach produced a proposal for a pilot project which is now an ongoing collaboration between Drs. Breytenbach and Patterstbe abstract from the draft is attached as an appendix to the report.

Dr. Pearce and Dr. Wyckoforked to determine the potential for performing pharmacogenomic analysis at UMKC, which would extend the reach of work that Dr. Mongi Benjeddou at UWC is currently performing. We were able to replicate the necessary resources for much of the project, buwere unable to locate the appropriate radiation source either at UMKC or at UM Columbia for the project. We are still working to find this necessary tool. However, while at UMKC, Dr. Pearce, Mr. Sante, and Ms. Shivani Gargvanshi (a current UMKC Graduatestudent) worked to determine the feasibility of nanopore sequencing for pharmacogenomics projects both here and at UWC. The proposed platform is cost

utilized to enhance the amount of research, the number of grants applied for and received, and the relationship with UWC will enable potential more applications and a wider field of potential comrercialization for such applications.

These opportunities are of course best pursued when there is mutual shared interest in the outcomes and potential grantsvailable Mutually beneficial projects will emerge which ultimately are funded and sustainable. Incorporation of these projects interfabric of the Precision Medicine Institute will increase the reach of the institute, enable greater funding (enabling funding from sources such as the NIH program and others) and open access to more international partnerships and global commercial tion opportunities.

An excellent opportunity for research funding the new DS Africa grant cycle that aunched at the NIH and this allowed Dr. Wyckoff to discuss potential jects while at UWC given the deadline of an August 25 LOI. That deadline was later a justed.

RFA Linkhttps://grants.nih.gov/grants/guide/rfafiles/RFARM-22-023.html

Building on this grampportunity and the lilely commercialization and R01 grants that are being submitted will cement sustainable funding for future life and health sciences research focused on precision medicine within the UMSAEP collaborative framework.

Bythe end of this experience, a Digrantwas submitted by the UWC group, with letters of support byDrs. Wyckoff and Uphoff, among other fricaspecific variants of Disease targets: An interactive platform and protein database for precision drug discovery, drug repurposing and biomarker development

Luke Zondagh, Samuel Egeyiah, Jacque Jouberts, and other UWC folks spearheaded the proposal and the UMSAEP supported experience was, I believe, crucial for the development of the grant.

Personagrowth

Ongoing Activities:

Centered around drug screening

Bringing in Iman Roomaney, Haly Holmes, and CHS personnel

Multiple grant opportunities implementation science and data analysis

Drs. Fisher, Joubert, Wyckoff

Our discussion noted that this would be an effective way to continue collaborations between the UWC and UMK Chools of Pharmacy, with an emphasis on shared infrastructure.

Appendix 1: papeabstractfrom Samson Ostesi

Appendix 2: Draft proposabstractfrom Dr. Breytenbach

Appendix 3Flyer